Aging Cell · 2016 · 166 citations · 44 references
EducationBiochemistryPharmacologyAgingGeriatric PharmacologyMetabolic RegulationAge-related Physiological ChangesAging PhysiologyBiological AgingCardiovascular AgingCellular AgingEndothelial DysfunctionAge-related Metabolic ChangesAge-related Oxidative StressImpaired Glucose ToleranceMtor InhibitionMtor SignalingProtein Kinase InhibitorsSenescenceVascular Endothelial Dysfunction
Inhibition of mammalian target of rapamycin, mTOR, extends lifespan and reduces age-related disease. It is not known what role mTOR plays in the arterial aging phenotype or if mTOR inhibition by dietary rapamycin ameliorates age-related arterial dysfunction. To explore this, young (3.8 ± 0.6 months) and old (30.3 ± 0.2 months) male B6D2F1 mice were fed a rapamycin supplemented or control diet for 6-8 weeks. Although there were few other notable changes in animal characteristics after rapamycin treatment, we found that glucose tolerance improved in old mice, but was impaired in young mice, after rapamycin supplementation (both P < 0.05). Aging increased mTOR activation in arteries evidenced by elevated S6K phosphorylation (P < 0.01), and this was reversed after rapamycin treatment in old mice (P < 0.05). Aging was also associated with impaired endothelium-dependent dilation (EDD) in the carotid artery (P < 0.05). Rapamycin improved EDD in old mice (P < 0.05). Superoxide production and NADPH oxidase expression were higher in arteries from old compared to young mice (P < 0.05), and rapamycin normalized these (P < 0.05) to levels not different from young mice. Scavenging superoxide improved carotid artery EDD in untreated (P < 0.05), but not rapamycin-treated, old mice. While aging increased large artery stiffness evidenced by increased aortic pulse-wave velocity (PWV) (P < 0.01), rapamycin treatment reduced aortic PWV (P < 0.05) and collagen content (P < 0.05) in old mice. Aortic adenosine monophosphate-activated protein kinase (AMPK) phosphorylation and expression of the cell cycle-related proteins PTEN and p27kip were increased with rapamycin treatment in old mice (all P < 0.05). Lastly, aging resulted in augmentation of the arterial senescence marker, p19 (P < 0.05), and this was ameliorated by rapamycin treatment (P < 0.05). These results demonstrate beneficial effects of rapamycin treatment on arterial function in old mice and suggest these improvements are associated with reduced oxidative stress, AMPK activation and increased expression of proteins involved in the control of the cell cycle.
44
Heart disease and stroke statistics--2015 update: a report from the American Heart Association.
Dariush Mozaffarian, Emelia J. Benjamin, Alan S. Go et al. · PubMed · 2015 · 8.3K citations
General Cardiovascular Risk Profile for Use in Primary Care
Ralph B. D’Agostino, Ramachandran S. Vasan, Michael Pencina et al. · Circulation · 2008 · 7.5K citations · Full text
Medicine, Cardiology, Risk Analysis +16
AMPK Phosphorylation of Raptor Mediates a Metabolic Checkpoint
Dana M. Gwinn, David B. Shackelford, Daniel F. Egan et al. · Molecular Cell · 2008 · 3.8K citations · Full text
Rapamycin fed late in life extends lifespan in genetically heterogeneous mice
Randy Strong, Z. Dave Sharp, James F. Nelson et al. · Nature · 2009 · 3.7K citations · Full text